Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Estimated Market Size of the Muscle Spasticity Market In 2029?

The market for muscle spasticity has seen substantial growth in recent years. It is projected to expand from $4.19 billion in 2024 to $4.57 billion in 2025 with a compound annual growth rate (CAGR) of 9.1%. This steady rise during the historical period can be ascribed to several factors including greater investment in R&D, growth in clinical indications, positive regulatory approvals and reimbursement schemes, a rising focus on the adoption of a multimodal strategy, and an increase in incidences of multiple sclerosis.

What Growth Rate Is Forecasted for the Muscle Spasticity Market by 2029?

The market for muscle spasticity is anticipated to exhibit substantial growth in the upcoming years, reaching a valuation of $6.41 billion by 2029 at a Compound Annual Growth Rate (CAGR) of 8.8%. The predicted growth in the forthcoming period can be associated with increasing emphasis on creating patient-focused care, widening distribution channels, emphasis on enhancing the quality of living, efforts towards producing targeted drug delivery systems, and the uncovering of biomarkers. Notable trends for the predicted period include the implementation of value-based reimbursement models, incorporation of artificial intelligence and machine learning technologies, uptake of telehealth and distant monitoring technologies, techniques of neurostimulation, and applications of regenerative medicine.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=18411&type=smp

Which Key Companies Are Shaping the Future of the Muscle Spasticity Market?

Major companies operating in the muscle spasticity market are F. Hoffmann-La Roche AG, AbbVie Inc., Abbott Laboratories, Novartis AG, Medtronic plc, Teva Pharmaceutical Industries Ltd., Boston Scientific Corporation, Sun Pharmaceutical Industries Ltd., Ipsen Pharma, Hikma Pharmaceuticals plc, Endo Pharmaceuticals Inc., Lupin Pharmaceuticals Inc., Amneal Pharmaceuticals Inc., Mallinckrodt Pharmaceuticals, Neurocrine Biosciences Inc., Merz Pharmaceuticals GmbH, Beximco Pharmaceuticals Ltd., ANI Pharmaceuticals Inc., Taj Pharmaceuticals Limited, Revance Therapeutics Inc., Acorda Therapeutics Inc., Mylan N.V., Camber Pharmaceuticals Inc., Saol Therapeutics Inc., Zydus Cadila

Which Factors Are Driving Demand in the Muscle Spasticity Industry?

The rise in occurrences of musculoskeletal ailments, which affect the body’s muscles, bones, and joints, resulting in pain, rigidity and movement disruptions, is forecasted to propel the muscle spasticity market. This upsurge is linked to various contributors such as the growing elderly population, inactive lifestyles, and escalation of chronic diseases. The purpose of muscle spasticity is to soothe the symptoms of these disorders by lessening pain, enhancing mobility, impeding complications, and boosting the general life quality and functional skills of patients. For instance, data from a study undertaken by The Lancet, a British medicinal journal in November 2023, highlighted that in 2020, approximately 494 million individuals worldwide were affected by varying musculoskeletal disorders, with projections depicting a likely 115% augment by 2050. Also, data from Amgen, an American biopharma firm in May 2022, predicted that the annual total of osteoporosis-induced fractures will surge by 68%, from 1.9 million in 2018 to 3.2 million by 2040. Hence, the surge in incidences of musculoskeletal conditions is stimulating the muscle spasticity market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=18411&type=smp

How Is the Muscle Spasticity Market Segmented by Several Divisions?

The muscle spasticity market covered in this report is segmented –

1) By Drug Type: Baclofen, Botulinum Toxin, Diazepam, Dantrolene Sodium, Other Drugs

2) By Route Of Administration: Oral, Intramuscular, Other Routes

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:

1) By Baclofen: Oral Baclofen, Intrathecal Baclofen (Pump)

2) By Botulinum Toxin: Botox (Botulinum Toxin Type A), Dysport (Botulinum Toxin Type A), Xeomin (Botulinum Toxin Type A), Myobloc (Botulinum Toxin Type B)

3) By Diazepam: Oral Diazepam, Injectable Diazepam

4) By Dantrolene Sodium: Oral Dantrolene, Injectable Dantrolene

5) By Other Drugs: Tizanidine, Clonidine, Gabapentin, Other Muscle Relaxants, Selective Serotonin Reuptake Inhibitors (SSRIs)

What are the Emerging Market Trends Driving the Growth of the Muscle Spasticity Industry?

Key businesses within the muscle spasticity market are concentrating their efforts on creating oral suspensions to address muscle spasms related to illnesses like multiple sclerosis and spinal cord injuries. Oral suspensions, which are liquid medications containing dispersed active elements that are ingested orally, are their primary focus. To illustrate, ANI Pharmaceuticals, a pharmaceutical production entity based in the US, unveiled a baclofen oral suspension in April 2024. This suspension, a generic version of fleqsuvy, is applied for alleviating muscle spasms precipitated by conditions such as multiple sclerosis and spinal cord injuries by aiding in muscle relaxation.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/muscle-spasticity-global-market-report

Which Regions Are Driving Growth in the Muscle Spasticity Market?

North America was the largest region in the muscle spasticity market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the muscle spasticity market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=18411

This Report Delivers Insight On:

1. How big is the muscle spasticity market, and how is it changing globally?

2. Who are the major companies in the muscle spasticity market, and how are they performing?

3. What are the key opportunities and risks in the muscle spasticity market right now?

4. Which products or customer segments are growing the most in the muscle spasticity market?

5. What factors are helping or slowing down the growth of the muscle spasticity market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model